THRX — Theseus Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00- $181.72m
- -$23.40m
- 42
- 36
- 15
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.81 | ||
| Price to Tang. Book | 0.81 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -29.23% | ||
| Return on Equity | -25.55% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Theseus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on treating cancer patients through the discovery, development, and commercialization of targeted therapies. Its development programs are designed to address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. It also focused on tyrosine kinase inhibitors (TKIs), which is rooted in the critical role that tyrosine kinases play in the development of cancer. It develops pan-variant kinase inhibitors-inhibitors that target cancer-causing and drug resistance mutations in clinically protein kinases. Its product candidate, THE-630, is a pan-variant inhibitor of all classes of activating and resistance mutations of the KIT kinase for the treatment of GIST, a type of cancer often characterized by oncogenic activation of KIT. It is also developing THE-349, a selective epidermal growth factor receptor inhibitor for the treatment of non-small cell lung cancer.
Directors
- Iain Dukes CHM (62)
- Timothy Clackson PRE (54)
- David Dalgarno CFD (59)
- Victor Rivera CFD
- David Kerstein EXO
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- December 29th, 2017
- Public Since
- October 7th, 2021
- No. of Shareholders
- 8
- No. of Employees
- 38
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 44,649,172
- Address
- 314 Main Street, Suite 04-200, CAMBRIDGE, 02142
- Web
- https://theseusrx.com/
- Phone
- +1 8574009491
- Auditors
- Ernst & Young LLP
Upcoming Events for THRX
Q1 2024 Theseus Pharmaceuticals Inc Earnings Release
Theseus Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Theseus Pharmaceuticals Inc Earnings Release
Similar to THRX
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
What is the Theseus Pharmaceuticals share price?
As of Today at 18:21 UTC, shares in Theseus Pharmaceuticals are trading at $4.07. This share price information is delayed by 15 minutes.
How has the Theseus Pharmaceuticals share price performed this year?
Shares in Theseus Pharmaceuticals last closed at $4.07 and the price had moved by -68.79% over the past 365 days. In terms of relative price strength the Theseus Pharmaceuticals share price has underperformed the S&P500 Index by -74.6% over the past year.
What are the analyst and broker recommendations for Theseus Pharmaceuticals?
The overall consensus recommendation for Theseus Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
What is the Theseus Pharmaceuticals dividend yield?
Theseus Pharmaceuticals does not currently pay a dividend.
Does Theseus Pharmaceuticals pay a dividend?
Theseus Pharmaceuticals does not currently pay a dividend.
When does Theseus Pharmaceuticals next pay dividends?
Theseus Pharmaceuticals does not currently pay a dividend.
How do I buy Theseus Pharmaceuticals shares?
To buy shares in Theseus Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Theseus Pharmaceuticals?
As of the previous close price of $4.07, shares in Theseus Pharmaceuticals had a market capitalisation of $181.72m.
Where are Theseus Pharmaceuticals shares listed?
Here are the trading details for Theseus Pharmaceuticals:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: THRX
What kind of share is Theseus Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Theseus Pharmaceuticals is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Theseus Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Theseus Pharmaceuticals is $5.25. That is 28.99% above the last closing price of $4.07.
Analysts covering Theseus Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$1.28 for the next financial year.
What is the trend in the Theseus Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Theseus Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +16.52%.
As of the last closing price of $4.07, shares in Theseus Pharmaceuticals were trading -19.06% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Theseus Pharmaceuticals PE Ratio?
The Theseus Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $4.07.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Theseus Pharmaceuticals?
Theseus Pharmaceuticals' management team is headed by:
- Iain Dukes - CHM
- Timothy Clackson - PRE
- David Dalgarno - CFD
- Victor Rivera - CFD
- David Kerstein - EXO